List prices of novel sickle cell drugs too high, report suggests

The Institute for Clinical and Economic Review (ICER; MA, USA) has published an evidence report concerning the comparative and cost–effectiveness of three novel interventions for sickle cell disease. In a recent evidence report, the Institute for Clinical and Economic Review (ICER; MA, USA) evaluated the comparative and cost–effectiveness of three novel interventions for sickle cell disease — crizanlizumab (Adakveo®), voxelotor (Oxbrytaâ„¢) and L-glutamine (Endari®). The report suggests that the list prices of these therapies may have been set too high for the clinical benefits they confer and significant discounts from these are required. Historically, research into sickle cell disease has...